COVID-19 Update

Details

Project Line:
New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.

Our COVID-19 Evidence Portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and increasing international scientific evidence related to this disease.

The following is a summary of the most recent information posted to our COVID-19 portal.

Reports

Bamlanivimab Implementation Panel

  • Bamlanivimab is authorized (with terms and conditions) by Health Canada to treat adult and pediatric patients 12 years of age or older with mild-to-moderate COVID-19.
  • CADTH is convening an implementation panel of interdisciplinary clinical specialists to provide advice on which patients are most likely to benefit from this treatment.
  • To inform panel discussions, CADTH completed a Technology Review to appraise the evidence on bamlanivimab from the BLAZE-1 trial.
  • To further inform decision-makers about developments in this therapeutic area, a Horizon Scan on virus-neutralizing monoclonal antibodies against COVID-19 is currently in development and will be published in December 2020.

Bamlanivimab in the Treatment of Outpatients With COVID-19: A Critical Appraisal of an Interim Analysis of the BLAZE-1 Trial

  • CADTH conducted a Health Technology Review on bamlanivimab, a drug authorized (with terms and conditions) by Health Canada to treat adult and pediatric patients 12 years of age or older with mild-to-moderate COVID-19.

Convalescent Plasma Therapy for the Treatment of COVID-19: A Review of Clinical Effectiveness

  • Convalescent plasma (CP) therapy is an intervention where plasma is collected from recovered COVID-19 patients in the hope that the disease-specific antibodies could help the recipient recover from COVID-19.
  • Evidence on the effectiveness of CP therapy for the treatment of COVID-19 is still in the early stages.
  • This report summarizes the current evidence and it will be updated monthly as a living review.

COVID-19 Impact on Intimate Partner Violence and Child Maltreatment

  • This report provides an overview of the evidence regarding the impact of COVID-19 and related restrictions on intimate partner violence and child maltreatment.
  • The report also includes information on risk factors for violence, access to support for those at risk, and measures to mitigate the risk of intimate partner violence and child maltreatment during this period.
  • The findings of this report are based on a focused literature review.

Public Health Interventions for the Prevention of COVID-19 in Schools: Guidelines

  • These citations related to public health interventions and prevention of COVID-19 in schools are intended to provide a preliminary quick start to enable more comprehensive searching, or to help frame questions or issues.
  • Overall, three evidence-based guidelines were identified.
  • If you would like to know more, please contact CADTH by email or our requests page.

COVID-19 News

Visit our news page to stay on top of all of the emerging information we are monitoring and updating.

CADTH Literature Searching Tools

To help conduct your COVID-19–related literature searches, see our COVID-19 Search Strings and our COVID-19 Grey Literature Resources.

Additional Resources

CADTH is pleased to showcase additional COVID-19 resources from our partner organizations and the Canadian federal, provincial, and territorial governments’ health jurisdictions:

  • Pan-Canadian Health Organizations
  • Federal, Provincial, and Territorial Information

CAN’T FIND WHAT YOU NEED? LET US KNOW

Canadian ministries and departments of health, publicly funded organizations responsible for health service delivery, and clinical society stakeholders are encouraged to submit a request or contact their CADTH Liaison Officer. We’re here to help.

The CADTH Weekly COVID-19 Update is intended to keep you informed about the latest information posted on the CADTH COVID-19 portal. You’re receiving this update because you’ve subscribed to our CADTH e-alert system.